Sign in now to see personalised content appear here.
You can also see your reading history and subscription details on your subscriber page.
Combined R&D spend of 35 mid-cap biotech companies increased by nearly US$2bn to reach a total of $9.7bn in 2014
The company recently received two US patents for potential treatments for retinal and neurological diseases
The number of NCEs approved in Europe increased again in 2014, with the spotlight on cancer drugs and treatments for unmet medical needs. Dr Sarah Houlton reviews the new entrants
The versatile product has many key features that add benefits to the development of pharmaceutical powders
Doubles laboratory space and increases workforce from 65 to 115 people
Since the adaptiQ ready-to-use-pharmaceutical vial concept was launched at CPhI in 2014, Schott has seen strong interest from its customers and positive feedback from the market, and is now ramping up production ready for commercial launch early in 2015
Growth of the pharma and biotech industries and an increasing number of new biologics products are driving growth
An international resource to develop expert networks for paediatric medicines using scarce available specialists is making progress thanks to initiatives on both sides of the Atlantic
Potential in LIDDS’ technology platform for development of new treatments for diseases where local administration is desirable
New technologies in the production of both small molecules and biological drugs are helping companies move towards continuous processes but the challenges are still significant. Susan Birks reports on recent process developments
The first technology of its kind to enable measuring of physiologic intracellular concentrations
When considering the lyophilisation of moisture-sensitive biopharmaceuticals, companies must not only consider the moisture transfer via the container but also the stopper, as Dr Heike Kofler, West Pharmaceutical Services, explains